Brundin, P., Duan, W.-M. & Sauer, H. in Functional Neural Transplantation (eds. Dunnett, S. B. & Björklund, A.) 9–46 (Raven, New York, 1994).
Annett, L. E. in Functional Neural Transplantation (eds. Dunnett, S. B. & Björklund, A.) 71–102 (Raven, New York, 1994).
Olanow, C. W., Kordower, J. H. & Freeman, T. B. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19, 102–109 (1996).
Lindvall, O. Cerebral implantation in movement disorders: State of the art. Mov. Disord. 14, 201–205 (1999).
Kordower, J. H. et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332, 1118–1124 (1995).
Kordower, J. H. et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov. Disord. 13, 383–393 (1998).
Carson, R. E. et al. Quantification of amphetamine-induced changes in [11C]Raclopride binding with continuous infusion. J. Cereb. Blood Flow Metab. 17, 437–447 (1997).
Koepp, M. J. et al. Evidence for striatal dopamine release during a videogame. Nature 393, 266–268 (1998).
Lindvall, O. et al. Transplantation of fetal dopamine neurons in Parkinson's disease: 1-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 31, 155–165 (1992).
Lindvall, O. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 35, 172–180 (1994).
Wenning, G. K. et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42, 95–107 (1997).
Seeman, P. et al. Human brain D1 and D2 receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1, 5–15 (1987).
Rinne, U. K. et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov. Disord. 5, 55–59 (1990).
Sawle, G. V., Playford, E. D., Brooks, D. J., Quinn, N. & Frackowiak, R. S. J. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism. Brain 116, 853–867 (1993).
Antonini, A. et al. [11C]-raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2 receptors. Neurology 44, 1325–1329 (1994).
Elsworth, J. H. et al. Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study. Brain Res. 795, 55–62 (1998).
Laruelle, M. et al. Microdialysis and SPECT measurements of amphetamine-induced release in nonhuman primates. Synapse 25, 1–14 (1997).
Gunn, R. N., Lammertsma, A. A., Hume, S. P. & Cunningham, V. J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6, 279–287 (1997).
Studholme, C., Derek, L. G. & Hawkes D.J. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med. Phys. 24, 25–35 (1997).
Brooks, D. J. et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann. Neurol. 28, 547–555 (1990).